SILLAJEN, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,010 KRW | -3.61% |
|
-15.22% | -33.50% |
| Sales 2022 | 5.01B 3.62M | Sales 2023 | 3.94B 2.84M | Capitalization | 620B 448M |
|---|---|---|---|---|---|
| Net income 2022 | -24.59B -17.76M | Net income 2023 | -20.37B -14.71M | EV / Sales 2022 | 131 x |
| Net cash position 2022 | 59.87B 43.23M | Net cash position 2023 | 39.6B 28.59M | EV / Sales 2023 | 147 x |
| P/E ratio 2022 |
-29.1
x | P/E ratio 2023 |
-30.4
x | Employees | 37 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 72.42% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -3.61% | ||
| 1 week | -15.22% | ||
| 1 month | -14.41% | ||
| 3 months | -15.49% | ||
| 6 months | -37.93% | ||
| Current year | -33.50% |
1 week
4 010.00
4 760.00
1 month
4 010.005 090.00
Current year
4 010.006 620.00
1 year
3 950.007 260.00
3 years
3 950.0016 550.00
5 years
3 950.0059 400.00
10 years
3 950.00152 300.00
| Managers | Title | Age | Since |
|---|---|---|---|
Eun-Sang Moon
CEO | Chief Executive Officer | 59 | 14-01-31 |
Kyung-Mi Yang
CTO | Chief Tech/Sci/R&D Officer | 58 | - |
Ji-Won Choi
CTO | Chief Tech/Sci/R&D Officer | 57 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Eun-Sang Moon
CEO | Chief Executive Officer | 59 | 14-01-31 |
Yong-Jae Jang
BRD | Director/Board Member | 57 | - |
Myung-Seok Song
BRD | Director/Board Member | 57 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 4,010 | -3.61% | 1,644,445 |
| 24-05-30 | 4,160 | +0.85% | 1,371,877 |
| 24-05-29 | 4,125 | -3.62% | 825,521 |
| 24-05-28 | 4,280 | -4.25% | 949,597 |
| 24-05-27 | 4,470 | -5.50% | 1,156,315 |
End-of-day quote Korea S.E., May 30, 2024
More quotes
SillaJen Inc is a Korea-based company primarily engaged in the research and development of oncolytic virus immunotherapeutics. The Companyâs major product is Pexa-Vec, which is in a global Phase 3 clinical trial that is used for the treatment of liver cancer. Additionally, it also offers oncolytic virus immunotherapeutics, including SJ-102, SJ-103, SJ-815, JX-929, JX-930, JX-963, JX-970 and others.970 and others.
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -33.50% | 298M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- A215600 Stock
